Literature DB >> 27748397

Immunogenic cell death in cancer and infectious disease.

Lorenzo Galluzzi1,2,3,4,5,6, Aitziber Buqué2,3,4,5,6, Oliver Kepp2,3,4,5,7, Laurence Zitvogel6,8,9,10, Guido Kroemer2,3,4,5,7,11,12.   

Abstract

Immunogenicity depends on two key factors: antigenicity and adjuvanticity. The presence of exogenous or mutated antigens explains why infected cells and malignant cells can initiate an adaptive immune response provided that the cells also emit adjuvant signals as a consequence of cellular stress and death. Several infectious pathogens have devised strategies to control cell death and limit the emission of danger signals from dying cells, thereby avoiding immune recognition. Similarly, cancer cells often escape immunosurveillance owing to defects in the molecular machinery that underlies the release of endogenous adjuvants. Here, we review current knowledge on the mechanisms that underlie the activation of immune responses against dying cells and their pathophysiological relevance.

Entities:  

Mesh:

Year:  2016        PMID: 27748397     DOI: 10.1038/nri.2016.107

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  129 in total

Review 1.  Assembly and localization of Toll-like receptor signalling complexes.

Authors:  Nicholas J Gay; Martyn F Symmons; Monique Gangloff; Clare E Bryant
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

Review 2.  In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

Authors:  Claire Vanpouille-Box; Karsten A Pilones; Erik Wennerberg; Silvia C Formenti; Sandra Demaria
Journal:  Vaccine       Date:  2015-07-03       Impact factor: 3.641

Review 3.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

Review 4.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

Review 5.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

6.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

7.  The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway.

Authors:  Pablo Cordano; Victoria Gillan; Sigrid Bratlie; Veronique Bouvard; Lawrence Banks; Massimo Tommasino; M Saveria Campo
Journal:  Virology       Date:  2008-06-02       Impact factor: 3.616

Review 8.  STING-dependent cytosolic DNA sensing pathways.

Authors:  Glen N Barber
Journal:  Trends Immunol       Date:  2013-12-02       Impact factor: 16.687

9.  Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Authors:  Yuting Ma; Laetitia Aymeric; Clara Locher; Stephen R Mattarollo; Nicolas F Delahaye; Pablo Pereira; Laurent Boucontet; Lionel Apetoh; François Ghiringhelli; Noëlia Casares; Juan José Lasarte; Goro Matsuzaki; Koichi Ikuta; Bernard Ryffel; Kamel Benlagha; Antoine Tesnière; Nicolas Ibrahim; Julie Déchanet-Merville; Nathalie Chaput; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  J Exp Med       Date:  2011-03-07       Impact factor: 14.307

10.  Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.

Authors:  Mara Cirone; Livia Di Renzo; Lavinia Vittoria Lotti; Valeria Conte; Pankaj Trivedi; Roberta Santarelli; Roberta Gonnella; Luigi Frati; Alberto Faggioni
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

View more
  706 in total

1.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.

Authors:  Kenzo Ohara; Takayuki Ohkuri; Takumi Kumai; Toshihiro Nagato; Yui Nozaki; Kei Ishibashi; Akemi Kosaka; Marino Nagata; Shohei Harabuchi; Mizuho Ohara; Kensuke Oikawa; Naoko Aoki; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype.

Authors:  Teresa S Kim; Edaise da Silva; Daniel G Coit; Laura H Tang
Journal:  Am J Surg Pathol       Date:  2019-06       Impact factor: 6.394

Review 3.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

4.  Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.

Authors:  Changlin Li; Hui Sun; Wei Wei; Qiuzi Liu; Yinglei Wang; Ying Zhang; Fuming Lian; Fangchao Liu; Chenchen Li; Kaicheng Ying; Hang Huo; Zhi Qi; Benyi Li
Journal:  Cell Oncol (Dordr)       Date:  2020-07-24       Impact factor: 6.730

Review 5.  Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies.

Authors:  Ignacio Morales-Orue; Rodolfo Chicas-Sett; Pedro C Lara
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-22

6.  Mycoplasma bovis-Induced Inhibition of Bovine Peripheral Blood Mononuclear Cell Proliferation Is Ameliorated after Blocking the Immune-Inhibitory Programmed Death 1 Receptor.

Authors:  Farhan S Cyprian; Steve Jimbo; Muhammad Suleman; Teresia Maina; Tracy Prysliak; Claire Windeyer; Jose Perez-Casal
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

7.  Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Authors:  Chiara Riganti; Marcello Francesco Lingua; Iris Chiara Salaroglio; Chiara Falcomatà; Luisella Righi; Deborah Morena; Francesca Picca; Daniele Oddo; Joanna Kopecka; Monica Pradotto; Roberta Libener; Sara Orecchia; Paolo Bironzo; Valentina Comunanza; Federico Bussolino; Silvia Novello; Giorgio Vittorio Scagliotti; Federica Di Nicolantonio; Riccardo Taulli
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

8.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

Review 9.  Cancer vaccines: translation from mice to human clinical trials.

Authors:  Hoyoung Maeng; Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

10.  Harnessing the Immunomodulatory Effects of Radiation in Urinary Bladder Cancer.

Authors:  Waseem Abbas; Vineeta Goel; Arun Verma; Vineet G Gupta; Ranga R Rao
Journal:  Cureus       Date:  2019-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.